Core Insights - Molecure achieved significant milestones in 2024, focusing on the development of innovative therapies, particularly OATD-01 and OATD-02, and plans to accelerate research and development efforts [1][2] Clinical Development - The international KITE clinical trial for OATD-01, targeting pulmonary sarcoidosis, has commenced with several patients already randomized, and recruitment is expanding across five centers in the USA and soon in Europe [3][5] - OATD-01 is also under consideration for partnership discussions, with several dozen meetings held with potential partners in 2024 [4] - The KITE trial is expected to provide critical data on the CHIT1 protein, which may have implications for other diseases, including MASH, projected to exceed $25 billion by 2032 [4][6] - The Phase II clinical trial for OATD-01 has been initiated, and efforts are underway to develop it for MASH treatment in partnership [5] - OATD-02 is progressing in Phase I trials, with no dose-limiting toxicity observed, allowing for continued dose escalation [7] Financial Performance - Molecure raised approximately PLN 30 million (around $7.72 million) through stock issuance in 2024, which will support ongoing clinical trials and operational activities [8][21] - Operating revenues for 2024 were PLN 2.9 million, down from PLN 3.7 million in 2023, while operating costs slightly decreased to PLN 35.2 million [21] Research and Development - The mRNA-targeted drug platform has validated two therapeutic targets, with plans to select lead compounds for further development [12] - Collaboration with Avicenna Biosciences is ongoing to optimize lead compounds in the USP7 program using AI tools [10] - Molecure is focusing on optimizing its organizational structure, reducing discovery-phase programs from five to three to concentrate resources on promising clinical assets [5] Business Development - In 2024, Molecure participated in several major industry conferences, holding numerous meetings with potential partners and investors, indicating strong interest in its clinical and preclinical programs [13][14] - The company plans to continue engaging in industry events in 2025 to further its business development efforts [21]